{"id":21567,"date":"2025-04-17T13:53:08","date_gmt":"2025-04-17T06:53:08","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=21567"},"modified":"2025-04-17T13:53:08","modified_gmt":"2025-04-17T06:53:08","slug":"brain-navi-begins-ipo-counseling-with-first-securities-inc-setting-the-stage-for-global-medtech-expansion","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=21567","title":{"rendered":"Brain Navi Begins IPO Counseling with First Securities Inc., Setting the Stage for Global MedTech Expansion"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ZHUBEI<\/span>, April 17, 2025<\/span><\/span> \/PRNewswire\/ — Brain\u00a0Navi Biotechnology Co., Ltd. (“Brain Navi<\/span>“) has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry.<\/p>\n

\n

\"Dr. <\/a>
Dr. Jerry Chen, CEO of Brain Navi, announced the IPO Consulting to enter the capital market.<\/span><\/p>\n<\/div>\n

Founded in 2015 and located in the Hsinchu Biomedical Science Park, Brain Navi<\/span> concentrates on innovating surgical robots and medical devices. By integrating machine vision, artificial intelligence (AI), and advanced navigation technologies, the company provides high-precision surgical solutions tailored to meet the evolving needs of modern healthcare. Over the years, Brain Navi<\/span> has established strong partnerships with leading medical institutions worldwide. Its innovations have garnered multiple international patents and regulatory approvals, with global expansion efforts already underway in Europe<\/span>, Asia<\/span>, Latin America<\/span>, and soon in the USA<\/span> market.<\/p>\n

The company’s flagship product, NaoTrac, is a neurosurgical navigation robot that combines AI, robotics, and computer vision to enhance surgical precision and reduce operative time. Brain Navi’s<\/span> portfolio also includes the KrystoLens, the single-use neuro-endoscope designed to improve safety and efficiency in minimally invasive brain surgery.<\/p>\n

Looking ahead, Brain Navi<\/span> plans to deepen collaborations with top-tier medical centers to refine its intelligent surgical systems. Through this IPO counseling process, the company aims to responsibly accelerate R&D and scale its innovations for broader clinical adoption, reinforcing its position as a next-generation leader in smart medical technology.<\/p>\n

First Securities Inc. expressed confidence in Brain Navi’s<\/span> growth potential. As global interest in surgical robotics continues to rise\u2014especially in neurosurgery, where accuracy is critical\u2014technologies that combine navigation and AI are poised to play a transformative role. The firm will provide continued guidance throughout Brain Navi’s<\/span> IPO journey, helping bring new investment opportunities to those who share a vision for the future of intelligent healthcare.<\/p>\n

\n<\/div>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ZHUBEI<\/span>, April 17, 2025<\/span><\/span> \/PRNewswire\/ — Brain\u00a0Navi Biotechnology Co., Ltd. (“Brain Navi<\/span>“) has officially begun IPO counseling with First Securities Inc., marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry.<\/p>\n

\n

\"Dr. <\/a>
Dr. Jerry Chen, CEO of Brain Navi, announced the IPO Consulting to enter the capital market.<\/span><\/p>\n<\/div>\n

Founded in 2015 and located in the Hsinchu Biomedical Science Park, Brain Navi<\/span> concentrates on innovating surgical robots and medical devices. By integrating machine vision, artificial intelligence (AI), and advanced navigation technologies, the company provides high-precision surgical solutions tailored to meet the evolving needs of modern healthcare. Over the years, Brain Navi<\/span> has established strong partnerships with leading medical institutions worldwide. Its innovations have garnered multiple international patents and regulatory approvals, with global expansion efforts already underway in Europe<\/span>, Asia<\/span>, Latin America<\/span>, and soon in the USA<\/span> market.<\/p>\n

The company’s flagship product, NaoTrac, is a neurosurgical navigation robot that combines AI, robotics, and computer vision to enhance surgical precision and reduce operative time. Brain Navi’s<\/span> portfolio also includes the KrystoLens, the single-use neuro-endoscope designed to improve safety and efficiency in minimally invasive brain surgery.<\/p>\n

Looking ahead, Brain Navi<\/span> plans to deepen collaborations with top-tier medical centers to refine its intelligent surgical systems. Through this IPO counseling process, the company aims to responsibly accelerate R&D and scale its innovations for broader clinical adoption, reinforcing its position as a next-generation leader in smart medical technology.<\/p>\n

First Securities Inc. expressed confidence in Brain Navi’s<\/span> growth potential. As global interest in surgical robotics continues to rise\u2014especially in neurosurgery, where accuracy is critical\u2014technologies that combine navigation and AI are poised to play a transformative role. The firm will provide continued guidance throughout Brain Navi’s<\/span> IPO journey, helping bring new investment opportunities to those who share a vision for the future of intelligent healthcare.<\/p>\n

\n<\/div>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-21567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21567"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/21567\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}